Targeting bile‐acid signalling for metabolic diseases
Open accessThe DOI matches its Crossref record; 165 of the 169 references it cites were found in a registry or an index.
Abstract
Bile acids are increasingly being appreciated as complex metabolic integrators and signalling factors and not just as lipid solubilizers and simple regulators of bile-acid homeostasis. It is therefore not surprising that a number of bile-acid-activated signalling pathways have become attractive therapeutic targets for metabolic disorders. Here, we review how the signalling functions of bile acids can be exploited in the development of drugs for obesity, type 2 diabetes, hypertriglyceridaemia and atherosclerosis, as well as other associated chronic diseases such as non-alcoholic steatohepatitis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Through FXR activation, OCA modulates bile acid synthesis, absorption, transport, secretion, and metabolism, with a net effect of choleresis.(157,158)”
From Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases (2019) · cites this paper as [157]
In the citing paper
“In animal models, FXR activation has demonstrated antifibrotic and anti-inflammatory properties as well.(157)”
From Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases (2019) · cites this paper as [157]
In the citing paper
“After conjugation with either taurine or glycine, primary bile acids are released into the intestine to assist with lipid digestion and are recycled back into the liver (Thomas et al., 2008).”
From The Microbiota-Gut-Brain Axis (2019) · cites this paper as Thomas et al., 2008
In the citing paper
“By activating nuclear farnesoid X receptor (FXR) and plasma membrane TGR5 receptor, bile acids were shown to regulate systemic lipid, cholesterol, and glucose metabolism, as well as energy and immune homeostasis (Calmus and Poupon, 2014;de Aguiar Vallim et al., 2013;Thomas et al., 2008).”
From The Microbiota-Gut-Brain Axis (2019) · cites this paper as Thomas et al., 2008
In the citing paper
“In addition, FXR regulates other pathways with direct antiinflammatory and antifibrotic effects. 13-15”
From A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis (2016) · cites this paper as [13]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
An obesity-associated gut microbiome with increased capacity for energy harvest
Turnbaugh, P. J., Ley, R. E., Mahowald, M. A., Magrini, V., Mardis, E. R., & Gordon, J. I. (2006) · Nature · doi:10.1038/nature05414 · Cited by 12,444
International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels
Catterall, W. A., Chandy, K. G., Clapham, D. E., Gutman, G. A., Hofmann, F., Harmar, A. J., Abernethy, D. R., & Spedding, M. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.4.5 · Cited by 7,126
SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15593 · Cited by 4,794
SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215593 · Cited by 4,092
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371
Identification of a nuclear receptor for bile acids
Makishima, M., Okamoto, A. Y., Repa, J. J., Tu, H., Learned, R. M., Luk, A., Hull, M. V., Lustig, K. D., Mangelsdorf, D. J., & Shan, B. (1999) · Science · doi:10.1126/science.284.5418.1362 · Cited by 2,714
Özcan, U., Yilmaz, E., Özcan, L., Furuhashi, M., Vaillancourt, E., Smith, R. O., Görgün, C. Z., & Hotamisligil, G. S. (2006) · Science · doi:10.1126/science.1128294 · Cited by 2,413
Bile Acids: Natural Ligands for an Orphan Nuclear Receptor
Parks, D. J., Blanchard, S. G., Bledsoe, R. K., Chandra, G., Consler, T. G., Kliewer, S. A., Stimmel, J. B., Willson, T. M., Zavacki, A. M., Moore, D. D., et al. (1999) · Science · doi:10.1126/science.284.5418.1365 · Cited by 2,274
Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation
Watanabe, M., Houten, S. M., Mataki, C., Christoffolete, M. A., Kim, B. W., Sato, H., Messaddeq, N., Harney, J. W., Ezaki, O., Kodama, T., et al. (2006) · Nature · doi:10.1038/nature04330 · Cited by 2,220
Self-citationThe Enzymes, Regulation, and Genetics of Bile Acid Synthesis
Russell, D. W. (2003) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.72.121801.161712 · Cited by 2,069
Research works printed but not linked: 1
- Harnish, D. C. et al. A synthetic farnesoid X receptor (FXR) agonist protects against diet-induced dyslipidemia. J. Clin. Lipidol. 1, 362 (2007).
Cited by
Items 401–500 of 1,002
Bile acid signaling through farnesoid X and TGR5 receptors in hepatobiliary and intestinal diseases
Stanimirov, B., Stankov, K., & Mikov, M. (2015) · Hepatobiliary & pancreatic diseases international · doi:10.1016/s1499-3872(14)60307-6 · Cited by 59
Nonalcoholic fatty liver disease: molecular pathways and therapeutic strategies
Huang, Y. Y., Gusdon, A. M., & Qu, S. (2013) · Lipids in Health and Disease · doi:10.1186/1476-511x-12-171 · Cited by 59
“[11,12] given the ability of FXR to antagonize inflammatory and fibrogenic processes.”
BackgroundStieger, B., & Geier, A. (2011) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2011.557067 · Cited by 59
“This may reflect the fact that serum bile salt levels are tightly interconnected with energy homeostasis [135,136].”
BackgroundLin, S., Yang, X., Yuan, P., Yang, J., Wang, P., Zhong, H., Zhang, X., Che, L., Feng, B., Li, J., et al. (2019) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.9b01332 · Cited by 57
Management of metabolic-associated fatty liver disease: The diabetology perspective
Jeeyavudeen, M. S., Khan, S. K., Fouda, S., & Pappachan, J. M. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i1.126 · Cited by 54
Zhang, J., Gupte, J., Gong, Y., Weiszmann, J., Zhang, Y., Lee, K. J., Richards, W. G., & Li, Y. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2016.12.016 · Cited by 54
“There are two bile acid biosynthetic pathways in the liver: the classic and the alternative; the former contributing to ∼75% of overall BA synthesis in mice (Russell and Setchell, 1992; Thomas et al., 2008).”
BackgroundSpatz, M., Ciocan, D. M., Merlen, G., Rainteau, D. P., Humbert, L., Gomes-Rochette, N. F., Hugot, C., Trainel, N., Mercier‐Nomé, F., Domenichini, S., et al. (2021) · JHEP Reports · doi:10.1016/j.jhepr.2021.100230 · Cited by 63
“This could have been expected, as TGR5 is reported to reduce MO migration and the MOs fromWTKO mice obviously still expressed TGR5.”
BackgroundProduction of New Microbially Conjugated Bile Acids by Human Gut Microbiota
García, C. J., Kosek, V., Beltrán, D., Tomás-Barberán, F. A., & Hajšlová, J. (2022) · Biomolecules · doi:10.3390/biom12050687 · Cited by 61
“Regarding the magnitude of BA hydrophobicity, the order would be UDCA < CA < CDCA < DCA < LCA [37].”
BackgroundGut microbiota metabolic reprogramming drives the development of metabolic diseases in the host
Wang, Y., Huang, B., Wei, X., Guan, Y., Li, L., Zheng, Y., & Sun, W. (2026) · Gut Microbes · doi:10.1080/19490976.2026.2644681 · Cited by 62
“64,65 Compared with primary BAs, secondary BAs exhibit weaker affinity for FXR, significantly attenuating gut FXR signaling.”
Bathena, S. P., Thakare, R. N., Gautam, N., Mukherjee, S., Olivera, M. A., Meza, J. L., & Alnouti, Y. (2014) · Toxicological Sciences · doi:10.1093/toxsci/kfu227 · Cited by 54
“In addition, amidation of BAs with glycine and taurine amino acids increases their solubility and reduces their toxicity (Chiang, 2009; Heuman et al., 1991; Thomas et al., 2008).”
BackgroundThe gut microbiota: a key regulator of metabolic diseases
Yang, J., & Kweon, M. (2016) · BMB Reports · doi:10.5483/bmbrep.2016.49.10.144 · Cited by 64
“mostly secreted into the lumen of the intestine to control the digestion and absorption of dietary fat and fat-soluble vitamins (36).”
BackgroundHilscher, M. B., Kamath, P. S., & Eaton, J. E. (2020) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2020.01.015 · Cited by 68
Recent advances in understanding and managing cholestasis
Wagner, M., & Trauner, M. (2016) · F1000Research · doi:10.12688/f1000research.8012.1 · Cited by 55
Yntema, T., Koonen, D. P. Y., & Kuipers, F. (2023) · Nutrients · doi:10.3390/nu15081850 · Cited by 59
“Of note, rodents produce additional forms of primary BAs in the liver—α- and β muricholic acids (MCAs) and ursodeoxycholic acid (UDCA)—which are derived from CDCA by mouse/rat-specific cytochrome P450 2C70 (Cyp2c70) [26,29].”
BackgroundInfluentialFlowers, S. A., & Ellingrod, V. L. (2015) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1640 · Cited by 52
Meyer-Gerspach, A. C., Steinert, R. E., Keller, S., Malarski, A., Schulte, F. H., & Beglinger, C. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-4109 · Cited by 52
“Bile acids (BAs), apart from their role in cholesterol homeostasis and dietary lipid absorption, can function as metabolic signaling molecules with potentially important effects on glucose homeostasis (1).”
BackgroundPatented TGR5 modulators: a review (2006 – present)
Gioiello, A., Rosatelli, E., Nuti, R., Macchiarulo, A., & Pellicciari, R. (2012) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2012.733000 · Cited by 58
“When the 23(S)-methyl group was next introduced in 6-ECDCA (Obeticholic acid, INT-747, 5) [37], a potent and selective FXR agonist in Phase III clinical studies for primary biliary cirrhosis (PBC) and non-alcoholic steatohepatitis (NASH), a reversal of the activity profile was observed.”
BackgroundInfluentialSelf-citationBile acid regulation: A novel therapeutic strategy in non-alcoholic fatty liver disease
Yu, Q., Jiang, Z., & Zhang, L. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.04.005 · Cited by 56
Yao, Z., Zhao, M., Gong, Y., Chen, W., Wang, Q., Fu, Y., Guo, T., Zhao, J., Gao, L., & Bo, T. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.00495 · Cited by 62
“Primary bile acid was converted from cholesterol in the liver and then conjugated to taurine or glycine and secreted into the bile by transport proteins (Thomas et al., 2008).”
BackgroundKunst, R. F., Verkade, H. J., Oude Elferink, R. P. J., & van de Graaf, S. F. J. (2021) · Hepatology · doi:10.1002/hep.31651 · Cited by 52
Xu, J., Li, X., Yao, X., Xie, S., Chi, S., Zhang, S., Cao, J., & Tan, B. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.813249 · Cited by 52
“In addition, BAs play an important role in lipid metabolism (15, 16), while the anti-NAFLD effects have been welldocumented by numerous studies in which BAs consumption reduced the weight of liver, serum and hepatic levels of total cholesterol (T-CHO) and TG, and improved morphological conditions of the liver in mice…”
BackgroundBile acid metabolism regulatory network orchestrates bone homeostasis
Xiang, T., Deng, Z., Yang, C. H., Tan, J., Dou, C., Luo, F., & Chen, Y. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106943 · Cited by 56
Marroncini, G., Naldi, L., Martinelli, S., & Amedei, A. (2024) · Biomedicines · doi:10.3390/biomedicines12071398 · Cited by 60
“Indeed, it has been demonstrated that the treatment with miRNAs released inhibiting PCSK1/3 expression, suppressing the GLP-1 production in enteroendocrine cells, which finally leads to increased IR [204,205].”
BackgroundFXR Primes the Liver for Intestinal FGF15 Signaling by Transient Induction of β-Klotho
Fu, T., Kim, Y., Byun, S., Kim, D.-H., Seok, S., Suino-Powell, K. M., Xu, H. E., KEMPER, B. W., & Kemper, J. K. (2015) · Molecular Endocrinology · doi:10.1210/me.2015-1226 · Cited by 59
Bhowmik, S., Jones, D. H., Chiu, H., Park, I., Chiu, H., Axelrod, H. L., Farr, C. L., Tien, H. J., Agarwalla, S., & Lesley, S. A. (2014) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.24353 · Cited by 50
Non-Alcoholic Fatty Liver Disease: Cause or Effect of Metabolic Syndrome
Grander, C., Grabherr, F., Moschen, A. R., & Tilg, H. (2016) · Visceral Medicine · doi:10.1159/000448940 · Cited by 59
Unraveling Host-Gut Microbiota Dialogue and Its Impact on Cholesterol Levels
Villette, R., Pukar, K. C., Béliard, S., Salas-Tapia, M. F., Rainteau, D. P., Guérin, M., & Lesnik, P. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00278 · Cited by 58
Enterohepatic circulation of bile acids and their emerging roles on glucolipid metabolism
Chen, M., Liu, C., Wan, Y., Yang, L., Jiang, S., Qian, D., & Duan, J. (2020) · Steroids · doi:10.1016/j.steroids.2020.108757 · Cited by 55
McMurdie, P. J., Stoeva, M. K., Justice, N., Nemchek, M. P., Sieber, C. M. K., Tyagi, S., Gines, J., Skennerton, C. T., Souza, M., Kolterman, O., et al. (2022) · BMC Microbiology · doi:10.1186/s12866-021-02415-8 · Cited by 58
“The bile acid receptors, farnesoid X receptor (FXR)] [33] and a G-protein-coupled receptor (TGR5) [34], have elicited considerable interest as targets in metabolic diseases [35], and there is now extensive support for microbiota-dependent modulation of these receptors via modification of bile acids [31].”
BackgroundLiu, J., Liu, J., Meng, C., Huang, C., Liu, F., & Xia, C. (2022) · Phytomedicine · doi:10.1016/j.phymed.2022.154173 · Cited by 51
The Gut Microbiome and Ferroptosis in MAFLD
Ji, J., Wu, L., Wei, J., Wu, J., & Guo, C. (2022) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2022.00136 · Cited by 68
Recent insights into the function and regulation of the bile salt export pump (ABCB11)
Stieger, B. (2009) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32832b677c · Cited by 52
Prawitt, J., Caron, S., & Staels, B. (2014) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2014.03.007 · Cited by 57
Al-Salami (2013) · Journal of Endocrinology and Diabetes Mellitus · doi:10.12970/2310-9971.2013.01.02.4 · Cited by 53
“An increase in BA pool size results in negative feedback mechanisms governed by nuclear receptors that will suppress the transcription of CYP7A1 (involved in BA synthesis) and CYP8B1 (which controls the production of CA) [53].”
InfluentialElevated NCOR1 disrupts a network of dietary-sensing nuclear receptors in bladder cancer cells
Abedin, S. A., Thorne, J. L., Battaglia, S., Maguire, O., Hornung, L. B., Doherty, A. P., Mills, I. G., & Campbell, M. J. (2009) · Carcinogenesis · doi:10.1093/carcin/bgp005 · Cited by 56
TGR5 in inflammation and cardiovascular disease
Pols, T. W. H. (2014) · Biochemical Society Transactions · doi:10.1042/bst20130279 · Cited by 57
Shih, D. M., Shaposhnik, Z., Meng, Y., Rosales, M., Wang, X., Wu, J., Ratiner, B., Zadini, F., Zadini, G., & Lusis, A. J. (2013) · The FASEB Journal · doi:10.1096/fj.12-223008 · Cited by 52
“Expressions of gluconeogenesis genes, Pepck and G6pase, whose expression are known to be decreased by both TGR5 (53) and SHP through the activation of FXR (54), were significantly lower in the HDCA group as compared with the chow group (Fig.”
ResultInfluentialBhowmik, S., Chiu, H., Jones, D. H., Chiu, H., Miller, M. D., Xu, Q., Farr, C. L., Ridlon, J. M., Wells, J. E., Elsliger, M., et al. (2016) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.24971 · Cited by 50
Guo, C., LaCerte, C., Edwards, J. E., Brouwer, K. R., & Brouwer, K. L. R. (2018) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.117.246033 · Cited by 56
“Bile acids are signaling molecules that modulate hepaticmetabolic and transporter function (Dawson et al., 2009), inflammation (Allen et al., 2011), and lipid, glucose, and energy homeostasis (Staels and Kuipers, 2007; Thomas et al., 2008; Lefebvre et al., 2009).”
BackgroundSpexin Acts as Novel Regulator for Bile Acid Synthesis
Lin, C., Zhao, L., Huang, T., Lü, L., Khan, M., Liu, J., Zhong, L. L. D., Cai, Z., Fan, B., Wong, A., et al. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.00378 · Cited by 55
“In ileum, bile acids are reabsorbed by ASBT and effluxed by OSTα/β into the portal vein (Thomas et al., 2008).”
BackgroundInfluentialShabgah, A. G., Norouzi, F., Hedayati‐Moghadam, M., Soleimani, D., Pahlavani, N., & Navashenaq, J. G. (2021) · Nutrition & Metabolism · doi:10.1186/s12986-021-00552-5 · Cited by 51
“Cytochrome P450 Family 8 Subfamily B Member 1 (Cyp8b1) is an important enzyme in the bile acid synthesis pathway, which determines the ratio of muricholic acid (MCA) and cholic acid (CA) as the two most abundant bile acids in the mouse [107, 108].”
BackgroundKloos, D., Lingeman, H., Mayboroda, O. A., Deelder, A. M., Niessen, W. M. A., & Giera, M. A. (2014) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2014.05.008 · Cited by 55
“Particularly in the context of metabolic diseases, such as obesity or type-2 diabetes, BA signaling might be exploited as a novel therapeutic intervention strategy [92,93].”
BackgroundNovel treatment modalities for nonalcoholic steatohepatitis
Satapathy, S. K., & Sanyal, A. J. (2010) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2010.08.003 · Cited by 52
González-Domínguez, R., García-Barrera, T., Vitorica, J., & Gómez-Ariza, J. L. (2015) · Biochimie · doi:10.1016/j.biochi.2015.01.005 · Cited by 49
Dysregulated signaling hubs of liver lipid metabolism reveal hepatocellular carcinoma pathogenesis
Lee, S., Mardinoğlu, A., Zhang, C., Lee, D., & Nielsen, J. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw462 · Cited by 50
“Intriguingly, from our signaling hub genes, we found both nuclear receptors and AMP-activated protein kinase (AMPK), which regulate other metabolic pathways: LXR (synonym: NR1H3) that regulates cholesterols and lipids (42,56), small heterodimer partner (SHP) (synonym: NR0B2) regulating bile acids (57), and AMPK1 and A…”
BackgroundLee, G., Lee, H., Hong, J., Lee, S. H., & Jung, B. H. (2016) · Journal of Chromatography B · doi:10.1016/j.jchromb.2016.07.017 · Cited by 53
Nurunnabi, M., Lee, S., Revuri, V., Hwang, Y. H., Kang, S. H., Lee, M., Cho, S., Cho, K.-J., Byun, Y., Bae, Y. H., et al. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.08.035 · Cited by 49
Perturbation of the circadian clock and pathogenesis of NAFLD
Mukherji, A., Dachraoui, M., & Baumert, T. F. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154337 · Cited by 57
“BA-signaling as a major regulator of TG, cholesterol and glucose homeostasis [71,72].”
BackgroundYin, C., Tang, S., Liu, L., Cao, A., Xie, J., & Zhang, H. (2021) · Animals · doi:10.3390/ani11030630 · Cited by 53
“In addition, since the hydrophobicity of BA determines their toxicity and protective effect [45], the BA profile of a BA compound can greatly affect its function.”
BackgroundTran, C. D., Grice, D. M., Wade, B., Kerr, C. A., Bauer, D. C., Li, D., & Hannan, G. N. (2015) · Future Microbiology · doi:10.2217/fmb.15.54 · Cited by 48
Marinozzi, M., Carotti, A., Sansone, E., Macchiarulo, A., Rosatelli, E., Sardella, R., Natalini, B., Rizzo, G., Adorini, L., Passeri, D., et al. (2012) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2012.04.021 · Cited by 49
Self-citationNTCP deficiency in mice protects against obesity and hepatosteatosis
Donkers, J. M., Kooijman, S., Slijepcevic, D., Kunst, R. F., Abbing, R. L. P. R., Haazen, L. C. J. M., de Waart, D. R., Levels, J. H. M., Schoonjans, K., Rensen, P. C. N., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.127197 · Cited by 48
“4 Introduction Bile acids, well-known for their pivotal role in dietary fat absorption, are increasingly recognized as complex and important hormonal contributors to many metabolic pathways (1-3).”
BackgroundSelf-citationYao, T., Gu, X., Liang, X., Fall, F. N., Cao, A., Zhang, S., Guan, Y., Sun, B., & Xue, M. (2021) · Aquaculture · doi:10.1016/j.aquaculture.2021.737012 · Cited by 50
Ji, G., Si, X., Dong, S., Xu, Y., Li, M., Yang, B., Tang, Z., Fang, X., Huang, L., Song, W., et al. (2021) · Nano Letters · doi:10.1021/acs.nanolett.1c01360 · Cited by 46
Yin, C., Xia, B., Tang, S., Cao, A., Liu, L., Zhong, R., Chen, L., & Zhang, H. (2021) · Frontiers in Nutrition · doi:10.3389/fnut.2021.747136 · Cited by 50
“Note that since the hydrophobicity of BA determines its toxicity and protective effect, the profile of the exogenous BA can greatly affect its function (72).”
BackgroundBile Acid Detection Techniques and Bile Acid-Related Diseases
Zhao, X., Liu, Z., Sun, F., Yao, L., Yang, G., & Wang, K. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.826740 · Cited by 50
“In addition, bile acids can also act as signaling molecules to regulate self-metabolism, lipid metabolism, energy balance, and glucose metabolism by binding to the “membrane bile acid receptor”—Takeda G protein-coupled receptor 5 (TGR5) and nuclear hormone receptors, such as farnesoid X receptor (FXR) (Thomas et al.,…”
BackgroundMeng, Y., Zheng, X., Fan, J., Cheng, W., Yan, T., Lai, Y., Zhang, N., Lu, Y., Qi, J., Huo, Z., et al. (2024) · Advanced Science · doi:10.1002/advs.202307981 · Cited by 66
Lee, B., Lee, S. M., Song, J. W., & Choi, J. W. (2024) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2024.009 · Cited by 49
“It will create secondary bile acids deoxy-cholic acid (DCA) from cholic acid(CA), lithocholic acid (LCA), and ursodeoxycholic acid (UDCA) from chenodeoxycholate (CDCA) for humans (Thomas et al ., 2008).”
BackgroundPiekarski, A., Decuypere, E. M. P., Buyse, J. G., & Dridi, S. (2016) · General and Comparative Endocrinology · doi:10.1016/j.ygcen.2016.03.007 · Cited by 52
Han, J., Dzierlenga, A. L., Lu, Z., Billheimer, D. D., Torabzadeh, E., Lake, A. D., Li, H., Novak, P., Shipkova, P., Aranibar, N., et al. (2017) · Obesity · doi:10.1002/oby.21855 · Cited by 47
“The interspecies differences in the hepatic bile acid pool composition may be a determinant in potential liver damage induced by the accumulation of specific bile acids in humans, which may be missing in rodent models (21,22).”
BackgroundGourley, M. E., & Kennedy, C. J. (2009) · Comparative Biochemistry and Physiology Part C Toxicology & Pharmacology · doi:10.1016/j.cbpc.2009.05.003 · Cited by 55
Nor-ursodeoxycholic acid reverses hepatocyte-specific nemo-dependent steatohepatitis
Beraza, N., Ofner-Ziegenfuss, L., Ehedego, H., Boekschoten, M., Bischoff, S. C., Mueller, M., Trauner, M., & Trautwein, C. (2011) · Gut · doi:10.1136/gut.2010.223834 · Cited by 47
“In addition, BAs have recently emerged as key metabolic regulators and integrators of hepatic lipid and glucose metabolism.(7) 23 At present, UDCA is the most frequently used anti-cholestatic drug in human cholestatic liver diseases.”
BackgroundNuclear receptors in liver fibrosis
Königshofer, P., Brusilovskaya, K., Petrenko, O., Hofer, B. S., Schwabl, P., Trauner, M., & Reiberger, T. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2021.166235 · Cited by 45
Li, X., Khan, I., Huang, G., Lu, Y., Wang, L., Liu, Y., Lu, L., Hsiao, W. L. W., & Liu, Z. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.174773 · Cited by 51
Dai, Z., Li, S., Meng, Y., Zhao, Q., Zhang, Y., Suonan, Z., Sun, Y., Shen, Q., Liao, X., & Xue, Y. (2022) · Nutrients · doi:10.3390/nu14204334 · Cited by 47
“Deoxycholic acid is a secondary bile acid produced by deconjugation and 7a-dehydroxylation by microbial enzymes in the colon [42].”
BackgroundBile acid metabolism and signaling: Emerging pharmacological targets of dietary polyphenols
Tveter, K. M., Mezhibovsky, E., Wu, Y., & Roopchand, D. E. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108457 · Cited by 53
Zangerolamo, L., Carvalho, M. U. W. B. D., & Barbosa, H. C. L. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26146547 · Cited by 61
“BA signaling is primarily driven by the nuclear farnesoid X receptor (FXR) and the membrane-bound Takeda G protein-coupled receptor 5 (TGR5) [4].”
Malabsorption as a Therapeutic Approach in Bariatric Surgery
Billeter, A. T., Fischer, L., Wekerle, A.-L., Senft, J. D., & Müller-Stich, B. P. (2014) · Visceral Medicine · doi:10.1159/000363480 · Cited by 60
Genetic variants in CYP7A1 and risk of myocardial infarction and symptomatic gallstone disease
Qayyum, F., Lauridsen, B. K., Frikke‐Schmidt, R., Kofoed, K. F., Nordestgaard, B. G., & Tybjærg‐Hansen, A. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy068 · Cited by 51
Budzik, B., Evans, K. A., Wisnoski, D. D., Jin, J. J., Rivero, R. A., Szewczyk, G. R., Jayawickreme, C. K., Moncol, D. L., & Yu, H. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.01.003 · Cited by 52
Emerging medical therapies for non-alcoholic fatty liver disease and for alcoholic hepatitis
Wong, V. W., & Singal, A. K. (2019) · Translational Gastroenterology and Hepatology · doi:10.21037/tgh.2019.06.06 · Cited by 49
“FXR, nuclear receptors expressed in the liver and small bowel mucosa, regulate lipid and bile acid metabolism (73), and provide anti-inflammatory hepato-protective effects, and decrease nitric oxide levels in microvasculature of the liver with consequent improvement in portal hypertension (74,75).”
BackgroundGanguli, S., Deleeuw, P., & Satapathy, S. K. (2019) · Hepatic Medicine Evidence and Research · doi:10.2147/hmer.s188991 · Cited by 49
“Farnesoid X Receptor (FXR) Agonists FXR has been identified as a receptor for bile acids and has been found to regulate lipid metabolism and modulate glucoregulatory pathways.(110,111) This is a relatively novel class of drug target being studied in the treatment of NAFLD and NASH.”
BackgroundThe Potential of Bile Acids as Biomarkers for Metabolic Disorders
Yin, C., Zhong, R., Zhang, W., Liu, L., Chen, L., & Zhang, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512123 · Cited by 49
“Besides, BAs themselves hold promise as indicators of health in gut–liver axis [15].”
BackgroundZhang, J., Kris‐Etherton, P. M., Thompson, J. T., Hannon, D. B., Gillies, P. J., & Heuvel, J. P. V. (2011) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2011.01.004 · Cited by 45
“Farnesoid-X-receptor has been studied extensively in hepatocytes and enterocytes due to its critical roles in bile acid synthesis, secretion and reabsorption [56].”
BackgroundMeng, Z., Wang, L., Chang, L., Sun, J., Bao, J., Li, Y., Chen, Y. E., & Lin, J. D. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.10.033 · Cited by 49
“Bile acids are efficiently recycled through the enterohepatic circulation to facilitate intestinal absorption of dietary fats (Thomas et al., 2008).”
BackgroundSynergistic anti-inflammatory effect of gut microbiota and lithocholic acid on liver fibrosis
Shao, J., Ge, T., Tang, C., Wang, G., Pang, L., & Chen, Z. (2022) · Inflammation Research · doi:10.1007/s00011-022-01629-4 · Cited by 47
“Bile acids are known to activate TGR5 signaling pathways to increase oxidative phosphorylation and ATP/ADP ratio [38].”
BackgroundLiu, A., Xu, C., Liu, Y., Sun, D., Jiang, L., Tang, L., Zhu, P., Chen, S., Liu, W., Wang, X., et al. (2023) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17362 · Cited by 51
Huang, C., Tan, H., Song, M., Liu, K., Liu, H., Wang, J., Shi, Y., Hou, F., Zhou, Q., Huang, R., et al. (2023) · Microbiome · doi:10.1186/s40168-023-01546-6 · Cited by 45
“Therefore, our study reveals a possible link between maternal WD intake and the risk of offspring developing CD. Abbreviations IBD Inflammatory Bowel Disease CD Crohn’s disease UC Ulcerative Colitis TNBS Trinitrobenzenesulfonic acid solution WD Western-style diet MWD Maternal Western diet ND Normal control diet IOD In…”
BackgroundPON3 knockout mice are susceptible to obesity, gallstone formation, and atherosclerosis
Shih, D. M., Yu, J. M., Vergnes, L., Dali‐Youcef, N., Champion, M. D., Devarajan, A., Zhang, P., Castellani, L. W., Brindley, D. N., Jamey, C., et al. (2014) · The FASEB Journal · doi:10.1096/fj.14-260570 · Cited by 54
“The significantly decreasedexpressionofCyp7a in the livers of Pon3KO mice could be due to the actions of the FXR-SHP-dependent pathway (50) and of FXR-independent pathways such as the inhibitory effects of inflammatory Figure 6.”
BackgroundSelf-citationKeitel, V., & Häussinger, D. (2013) · Current Opinion in Gastroenterology · doi:10.1097/mog.0b013e32835f3f14 · Cited by 45
Enhancing cellulose functionalities by size reduction using media-mill
Dubey, R., Toh, Y., & Yeh, A. (2018) · Scientific Reports · doi:10.1038/s41598-018-29777-w · Cited by 48
Pham, H. T., Arnhard, K., Asad, Y. J., Deng, L., Felder, T. K., St John-Williams, L., Kaever, V., Leadley, M., Mitro, N., Muccio, S., et al. (2016) · The Journal of Applied Laboratory Medicine · doi:10.1373/jalm.2016.020537 · Cited by 43
“It is of utmost importance in the development of metabolic signatures in preclinical pharmaceutical research for drug development (19).”
BackgroundRegulation of cholesterol biosynthesis and lipid metabolism: A microRNA management perspective
Bhattarai, A., Likos, E., Weyman, C. M., & Shukla, G. C. (2021) · Steroids · doi:10.1016/j.steroids.2021.108878 · Cited by 46
Régnier, M., Hul, M. V., Roumain, M., Paquot, A., d’Oplinter, A. D. W., Suriano, F., Everard, A., Delzenne, N. M., Muccioli, G. G., & Cani, P. D. (2023) · Gut Microbes · doi:10.1080/19490976.2023.2178796 · Cited by 46
Sun, C., Zhou, X., Guo, T., & Meng, J. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1168818 · Cited by 53
“The gut microbiota can modulate the expression of CYP7A1, CYP7B1, and CYP27A1, thereby influencing BA metabolites (59, 60).”
BackgroundLi, H., & Li, C. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1184734 · Cited by 51
“Lachnoclostridium, as a member of Lachnospiraceae, are also implied in BAs transformation (Thomas et al., 2008).”
BackgroundEffects of Chemical Modification of Ursodeoxycholic Acid on TGR5 Activation
Iguchi, Y., Nishimaki‐Mogami, T., Yamaguchi, M., Teraoka, F., Kaneko, T., & Une, M. (2011) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.34.1 · Cited by 44
Recent insights into farnesoid X receptor in non-alcoholic fatty liver disease
Xu, J., Li, Z.-P., Zhang, L., & Ji, G. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i37.13493 · Cited by 48
Probing the Binding Site of Bile Acids in TGR5
Macchiarulo, A., Gioiello, A., Thomas, C., Pols, T. W. H., Nuti, R., Ferrari, C., Giacchè, N., Franco, F., Pruzanski, M., Auwerx, J. H., et al. (2013) · ACS Medicinal Chemistry Letters · doi:10.1021/ml400247k · Cited by 47
Self-citationSeok, S., Kanamaluru, D., Xiao, Z., Ryerson, D., Choi, S., Suino-Powell, K. M., Xu, H. E., Veenstra, T. D., & Kemper, J. K. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.452037 · Cited by 49
Urinary Bile Acids as Biomarkers for Liver Diseases II. Signature Profiles in Patients
Bathena, S. P., Thakare, R. N., Gautam, N., Mukherjee, S., Olivera, M. A., Meza, J. L., & Alnouti, Y. (2014) · Toxicological Sciences · doi:10.1093/toxsci/kfu228 · Cited by 47
“In general, hepatotoxicity caused by monohydroxy BA (LCA) is the highest, followed by dihydroxy BA (CDCA and DCA), and then trihydroxy BA (CA) (Song et al., 2011; Thomas et al., 2008).”
BackgroundZhang, J., & Li, Y. (2015) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2015.09.007 · Cited by 44
Susukida, T., Sekine, S., Nozaki, M., Tokizono, M., & Ito, K. (2015) · Drug Metabolism and Disposition · doi:10.1124/dmd.115.065425 · Cited by 45
“…because taurine-conjugated BA species (nontoxic) were predominant in rodents, whereas glycine-conjugated BAs (toxic) were predominant in humans (Thomas et al., 2008; Marion et al., 2012), and 2) adaptive changes in the expression levels of enzymes and transporters occur in Bsep knockout mice…”
BackgroundDi, S., Wang, Y., Han, L., Bao, Q. D., Gao, Z., Wang, Q., Yang, Y., Zhao, L., & Tong, X. (2019) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2019/2958920 · Cited by 46
Lechner, S., Yee, M. F., Limketkai, B. N., & Pham, E. A. (2020) · Digestive Diseases and Sciences · doi:10.1007/s10620-020-06100-0 · Cited by 44
Ding, L., Zhang, L., Shi, H.-H., Wang, C., Jiang, X., Xue, C., Yanagita, T., Zhang, T., & Wang, Y.-M. (2020) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.9b08296 · Cited by 44
Zhang, Z., Fan, S., Huang, D., Xiong, T., Nie, S., & Xie, M. (2020) · Food & Function · doi:10.1039/d0fo01435d · Cited by 44
Bile Acids Have the Gall to Function as Hormones
Vallim, T. Q. D. A., & Edwards, P. A. (2009) · Cell Metabolism · doi:10.1016/j.cmet.2009.08.005 · Cited by 46
“In contrast, activation of TGR5 in enteroendocrine L cells that are scattered throughout the jejunum, ileum, and colon stimulates the secretion of the incretin glucagon-like peptide-1 (GLP-1) (reviewed in Thomas et al., 2008).”
BackgroundHumbert, L., Rainteau, D. P., Tuvignon, N., Wolf, C., Seksik, P., Laugier, R., & Carrière, F. (2018) · Journal of Lipid Research · doi:10.1194/jlr.m084830 · Cited by 44
“They have become attractive therapeutic targets for metabolic disorders and useful markers of hepatobiliary and intestinal diseases (16).”
BackgroundZhang, Z., Yang, L., Wan, Y., Liu, C., Jiang, S., Shang, E., & Duan, J. (2021) · Journal of Chromatography B · doi:10.1016/j.jchromb.2021.122728 · Cited by 41
Metadata
- Authors
- Thomas, C., Pellicciari, R., Pruzanski, M., Auwerx, J., & Schoonjans, K.
- Affiliations
- Institut de génétique et de biologie moléculaire et cellulaire (FR)
- University of Perugia (IT)
- Intercept Pharmaceuticals (United States) (US)
- Corresponding author
- Auwerx, Johan
- Schoonjans, Kristina
- Venue
- Nature Reviews Drug Discovery
- Published
- 2008-08
- Volume
- 7
- Issue
- 8
- Pages
- 678-693
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2078810890
- Cited by
- 1,422
- References
- 169
- Citations by year
- 2026: 81 · 2025: 92 · 2024: 106 · 2023: 107 · 2022: 113 · 2021: 90 · 2020: 83 · 2019: 82 · 2018: 78 · 2017: 81 · 2016: 75 · 2015: 75 · 2014: 71 · 2013: 77 · 2012: 47
- FWCI
- 5.13
- Type
- journal article
- Language
- en
- Open access
- green
- infoscience.epfl.ch
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Infoscience (Ecole Polytechnique Fédérale de Lausanne) (submittedVersion)
- Infoscience (Ecole Polytechnique Fédérale de Lausanne) (submittedVersion, cc-by-nc-nd)
- Funders
- European Commission
- Institut National de la Santé et de la Recherche Médicale
- Fondation pour la Recherche Médicale
- Ligue Contre le Cancer
- Centre National de la Recherche Scientifique
- Société Française de Nutrition
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Pharmacology (medical) › Berberine and alkaloids research
- Keywords
- bile acids, bile acid signaling, metabolic disorders, obesity, type 2 diabetes, hypertriglyceridemia, atherosclerosis, nonalcoholic steatohepatitis, therapeutic target, drug development
- MeSH terms
- Animals, Bile Acids and Salts, Humans, Metabolic Diseases, Signal Transduction, Drug Delivery Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.